Upgrade to SI Premium - Free Trial

Relay Therapeutics (RLAY)

13.65 +0.13 (0.96%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June May 27, 2026 4:05 PM - StreetInsider Relay Therapeutics (RLAY) PT Raised to $28 at H.C. Wainwright May 26, 2026 6:51 AM - StreetInsider Relay Therapeutics (RLAY) PT Raised to $26 at Guggenheim May 26, 2026 6:41 AM - StreetInsider Form 8-K Relay Therapeutics, Inc. For: May 20 May 21, 2026 5:08 PM - SEC Filing Form 424B5 Relay Therapeutics, Inc. May 21, 2026 4:12 PM - SEC Filing Relay Therapeutics prices $275 million public stock offering at $12 per share May 20, 2026 8:21 PM - StreetInsider Relay Therapeutics Announces Pricing of Public Offering of Common Stock May 20, 2026 8:21 PM - Globe NewsWire Relay Therapeutics (RLAY) PT Raised to $27 at Barclays May 20, 2026 4:19 AM - StreetInsider Relay Therapeutics (RLAY) PT Raised to $21 at Citizens on Zovegalisib Top-line Data May 20, 2026 4:06 AM - StreetInsider Form 424B5 Relay Therapeutics, Inc. May 19, 2026 5:16 PM - SEC Filing Relay Therapeutics launches $175 million stock offering May 19, 2026 4:03 PM - StreetInsider Relay Therapeutics Announces Proposed Public Offering of Common Stock May 19, 2026 4:03 PM - Globe NewsWire Jones Trading Upgrades Relay Therapeutics (RLAY) to Buy May 19, 2026 3:04 PM - StreetInsider Form 8-K Relay Therapeutics, Inc. For: May 19 May 19, 2026 8:46 AM - SEC Filing Relay Therapeutics reports positive data for vascular anomaly drug May 19, 2026 6:01 AM - StreetInsider Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies May 19, 2026 6:00 AM - Globe NewsWire Form SCHEDULE 13G/A Relay Therapeutics, Inc. Filed by: Point72 Asset Management, L.P. May 15, 2026 4:30 PM - SEC Filing Form 4 Relay Therapeutics, Inc. For: May 14 Filed by: Catinazzo Thomas May 14, 2026 6:45 PM - SEC Filing Form 144 Relay Therapeutics, Inc. Filed by: Catinazzo Thomas May 14, 2026 4:24 PM - SEC Filing Form 10-Q Relay Therapeutics, Inc. For: Mar 31 May 5, 2026 4:16 PM - SEC Filing Form 8-K Relay Therapeutics, Inc. For: May 05 May 5, 2026 4:10 PM - SEC Filing Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates May 5, 2026 4:05 PM - StreetInsider Form 4 Relay Therapeutics, Inc. For: Apr 28 Filed by: Catinazzo Thomas April 30, 2026 4:27 PM - SEC Filing Form 4 Relay Therapeutics, Inc. For: Apr 28 Filed by: Rahmer Peter April 30, 2026 4:27 PM - SEC Filing Form 4 Relay Therapeutics, Inc. For: Apr 28 Filed by: Bergstrom Donald A April 30, 2026 4:25 PM - SEC Filing Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026 April 29, 2026 4:05 PM - StreetInsider Relay Therapeutics (RLAY) PT Raised to $25 at H.C. Wainwright April 29, 2026 6:57 AM - StreetInsider Form ARS Relay Therapeutics, Inc. For: Dec 31 April 28, 2026 4:16 PM - SEC Filing Form DEFA14A Relay Therapeutics, Inc. April 28, 2026 4:10 PM - SEC Filing Form DEF 14A Relay Therapeutics, Inc. For: Jun 09 April 28, 2026 4:06 PM - SEC Filing Relay Therapeutics (RLAY) PT Raised to $22 at Goldman Sachs April 28, 2026 6:10 AM - StreetInsider Relay Therapeutics (RLAY) PT Raised to $21 at Wells Fargo April 28, 2026 5:24 AM - StreetInsider Relay Therapeutics (RLAY) PT Raised to $19 at Citizens -Triplet Update a 'Strong Positive' April 28, 2026 4:12 AM - StreetInsider Relay Therapeutics (RLAY) PT Raised to $18 at Oppenheimer April 27, 2026 4:30 PM - StreetInsider Relay Therapeutics (RLAY) PT Raised to $23 at Raymond James April 27, 2026 10:51 AM - StreetInsider Form 8-K Relay Therapeutics, Inc. For: Apr 27 April 27, 2026 9:16 AM - SEC Filing Relay announces plans for Phase 3 breast cancer trial of drug combination April 27, 2026 6:00 AM - StreetInsider Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer April 27, 2026 6:00 AM - Globe NewsWire Relay Therapeutics (RLAY) PT Raised to $22 at Jefferies April 23, 2026 10:21 AM - StreetInsider Form PRE 14A Relay Therapeutics, Inc. For: Jun 09 April 16, 2026 4:06 PM - SEC Filing Jones Trading Starts Relay Therapeutics (RLAY) at Hold April 13, 2026 4:09 PM - StreetInsider Form SCHEDULE 13G Relay Therapeutics, Inc. Filed by: PERCEPTIVE ADVISORS LLC April 13, 2026 4:00 PM - SEC Filing Form 4 Relay Therapeutics, Inc. For: Apr 07 Filed by: Catinazzo Thomas April 9, 2026 8:55 PM - SEC Filing Relay Therapeutics (RLAY) PT Raised to $21 at Barclays April 8, 2026 3:54 AM - StreetInsider Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 April 2, 2026 4:05 PM - StreetInsider Form SCHEDULE 13G/A Relay Therapeutics, Inc. Filed by: VANGUARD GROUP INC March 27, 2026 11:35 AM - SEC Filing Relay Therapeutics (RLAY) PT Raised to $19 at H.C. Wainwright March 23, 2026 6:43 AM - StreetInsider Raymond James on Relay (RLAY): ' ~60% upside to Relay’s current stock price, and we think with further derisking for a 1L breast cancer study that is conservative' March 20, 2026 9:48 AM - StreetInsider Form SCHEDULE 13G Relay Therapeutics, Inc. Filed by: PERCEPTIVE ADVISORS LLC March 19, 2026 4:08 PM - SEC Filing Relay Therapeutics (RLAY) PT Raised to $17 at Wells Fargo March 17, 2026 6:57 AM - StreetInsider Relay Therapeutics (RLAY) PT Raised to $17 at Citizens Following ESMO-TAT Update March 17, 2026 5:20 AM - StreetInsider Oppenheimer reiterates Outperform on Relay Therapeutics (RLAY) as zovegalisib shows 11.1-month PFS March 16, 2026 4:37 PM - StreetInsider Form 8-K Relay Therapeutics, Inc. For: Mar 16 March 16, 2026 8:31 AM - SEC Filing Relay Therapeutics reports phase 3 trial data for breast cancer drug March 16, 2026 7:00 AM - StreetInsider Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 March 16, 2026 7:00 AM - StreetInsider Relay Therapeutics (RLAY) PT Raised to $22 at Guggenheim March 13, 2026 7:59 AM - StreetInsider Form 4 Relay Therapeutics, Inc. For: Mar 09 Filed by: Catinazzo Thomas March 11, 2026 4:32 PM - SEC Filing Form 8-K Relay Therapeutics, Inc. For: Mar 06 March 11, 2026 4:15 PM - SEC Filing Full Article List